Cas:80906-67-8 1-[3-(Trimethoxysilyl)propyl]-1H-pyrrole manufacturer & supplier

Chemical Name:1-[3-(Trimethoxysilyl)propyl]-1H-pyrrole

CAS.NO:80906-67-8

Synonyms:1H-Pyrrole, 1-[3-(trimethoxysilyl)propyl]-;1H-Pyrrole,1-[3-(trimethoxysilyl)propyl];N-(3-TRIMETHOXYSILYLPROPYL)PYRROLE;1-[3-(Trimethoxysilyl)propyl]-1H-pyrrole;N-1-[3-(trimethoxysilyl)propyl]pyrrole

Molecular Formula:C₁₀H₁₉NO₃Si

Molecular Weight:229.348

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:247.4±23.0 °C at 760 mmHg

Density:1.0±0.1 g/cm3

Index of Refraction:1.454

PSA:32.62000

Exact Mass:229.113419

LogP:1.56

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1H-Pyrrole, 1-[3-(trimethoxysilyl)propyl]- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-1-[3-(trimethoxysilyl)propyl]pyrrole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1H-Pyrrole,1-[3-(trimethoxysilyl)propyl] Use and application,1H-Pyrrole, 1-[3-(trimethoxysilyl)propyl]- technical grade,usp/ep/jp grade.

Related News: While they are early data, “it’s also very reassuring that those patients who have progressed can be rather easily reinduced into remission,” Tendler said. J&J and AbbVie are now taking the same approach for the GLOW study, he added. 1-[3-(Trimethoxysilyl)propyl]-1H-pyrrole manufacturer The FDA has granted so-called accelerated approval in more than 250 instances since 1992, mainly for rare diseases or small patient populations that have had no effective treatments available to them. In these cases, the agency requires that drugmakers conduct additional clinical trials to prove their therapy works, or face withdrawal from the market. 1-[3-(Trimethoxysilyl)propyl]-1H-pyrrole supplier ��No two studies are the same, and each carries its own unique risks and presents individual challenges, but the aim of CTSuccess is to use the experience we have as a company in supplying materials for thousands of trials to identify the characteristics of a project upfront and highlight potential risk factors that may arise,�� said Kristen Devito, Global Director, Catalent Clinical Supply Services. 1-[3-(Trimethoxysilyl)propyl]-1H-pyrrole vendor While they are early data, “it’s also very reassuring that those patients who have progressed can be rather easily reinduced into remission,” Tendler said. J&J and AbbVie are now taking the same approach for the GLOW study, he added. 1-[3-(Trimethoxysilyl)propyl]-1H-pyrrole factory The FDA has granted so-called accelerated approval in more than 250 instances since 1992, mainly for rare diseases or small patient populations that have had no effective treatments available to them. In these cases, the agency requires that drugmakers conduct additional clinical trials to prove their therapy works, or face withdrawal from the market.